Clik here to view.
武田公布2016财年全年业绩，更新2017财年展望
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited)(TOKYO: 4502)： 盈利较去年有大幅增长...
View ArticleClik here to view.
武田薬品、ALUNBRIG™（ブリガチニブ）のピボタル第2相ALTA臨床試験のデータがジャーナル・オブ・クリニカル・オンコロジーに掲載と発表
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社(TSE: 4502)は本日、クリゾチニブ抵抗性で未分化リンパ腫キナーゼ陽性（ALK+）の局所進行性／転移性非小細胞肺がん（NSCLC）患者でALUNBRIG™（ブリガチニブ）を評価するピボタル第2相ALTA（ALK in Lung Cancer Trial of...
View ArticleClik here to view.
Boehringer Ingelheim strengthens early science portfolio through...
INGELHEIM, Germany & BEIJING, China Boehringer Ingelheim and Peking University (PKU) today announced an ambitious strategic partnership with the aim of jointly advancing early science innovation...
View ArticleClik here to view.
CANbridge and AmoyDx Enter into Strategic Partnership for CAN008 Companion...
BEIJING CANbridge Life Sciences and Amoy Diagnostics announced that they have entered into a strategic partnership to develop a companion diagnostic assay for CANbridge’s lead candidate, CAN008, a...
View ArticleClik here to view.
Dr. Reddy’s Laboratories Announces USFDA Approval for the Launch of...
HYDERABAD, India & PRINCETON, N.J. Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has received approval from the U.S. Food and Drug Administration...
View ArticleClik here to view.
Chi-Med Presents Clinical Data at ASCO 2017 Annual Meeting
LONDON Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that new clinical data on three of its novel tyrosine kinase inhibitors, fruquintinib, savolitinib and...
View ArticleClik here to view.
Company Profile for Laurus Labs Limited
Laurus is a leading research and development driven pharmaceutical company in India. The Company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical...
View ArticleClik here to view.
CANbridge Life Sciences Raises $25 Million in Series B Round Led by Lapam...
BEIJING CANbridge Life Sciences, a clinical-stage biopharmaceutical company focused on developing Western drug candidates in China and North Asia, announced that it raised $25 million in a Series B...
View ArticleClik here to view.
Dompé Receives Positive CHMP Opinion in Europe For Oxervate® (Cenegermin Eye...
MILAN Today, the biopharmaceutical company Dompé has announced that the Committee for Human Medicinal Products (CHMP) of EMA (European Medicines Agency) has released a positive opinion, recommending...
View ArticleClik here to view.
Takeda Showcases Broadened Oncology Portfolio Through Data Presentations at...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the company will feature new clinical analyses and outcomes research during three upcoming...
View ArticleClik here to view.
Clik here to view.
Dompé用于治疗中度或重度神经营养性角膜炎成人患者的Oxervate®（Cenegermin滴眼液）获得欧盟CHMP肯定意见
米兰 (美国商业资讯) — 生物制药公司Dompé今天宣布，EMA（欧洲药品署）人用药品委员会(CHMP)发布了一项肯定意见，建议签发Oxervate®（cenegermin...
View ArticleClik here to view.
EpimAb Biotherapeutics Collaborates with WuXi Biologics to Advance Lead...
SHANGHAI EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, and WuXi Biologics, a WuXi AppTec Affiliate, announced today a...
View ArticleClik here to view.
岸迈生物携手药明生物推进创新双抗药物进入临床开发
中国，上海 今天，岸迈生物科技有限公司（EpimAb Biotherapeutics）宣布与药明康德关联公司药明生物达成战略合作协议，共同推进岸迈生物的第一个创新双抗药物EMB-01于2018年进入新药临床申报。...
View ArticleClik here to view.
Clik here to view.
SpaceOAR®システムが日本で承認を取得
米マサチューセッツ州ベッドフォード （ビジネスワイヤ） 放射線療法において放射線のリスクから臓器を離し保護するための専有技術である吸収性ハイドロゲルを開発・製造・販売する医療技術企業のAugmenix,...
View ArticleClik here to view.
Takeda and Seattle Genetics Announce Lancet Publication of Phase 3 ALCANZA...
CAMBRIDGE, Mass. & OSAKA, Japan & BOTHELL, Wash. Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the randomized...
View ArticleClik here to view.
Astellas and Pfizer Announce Amendment to Clinical Research Protocol for...
TOKYO & NEW YORK Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Pfizer Inc. (NYSE:PFE) announced today the amendment of the protocol for the...
View ArticleClik here to view.
口服IDHIFA® (enasidenib) 1期试验的更新数据显示IDH2突变的复发或难治AML患者的完全缓解率和缓解持续时间
芝加哥 (美国商业资讯) — Celgene Corporation (NASDAQ:CELG)与Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)今天发布了进行中的1期剂量递增和扩展研究的有效性及安全性新数据，该研究评估口服研究药物IDHIFA® (enasidenib)用于异柠檬酸脱氢酶-2 (IDH2)突变的复发或难治急性粒细胞性白血病(R/R...
View ArticleClik here to view.
Exelixis Announces Initiation of Phase 1b Trial of Cabozantinib in...
SOUTH SAN FRANCISCO, Calif. Exelixis, Inc. (NASDAQ:EXEL) today announced the initiation of the dose-escalation stage of a phase 1b trial of cabozantinib in combination with atezolizumab (TECENTRIQ®)...
View Article